The Investigators propose to carry out a randomized, double-blind trial to compare the clinical efficacy of an individualized connectome-guided accelerated iTBS vs an anatomically-guided (Beam F3) accelerated iTBS. The study team will recruit both inpatients and outpatients who had been referred for TMS for the treatment of depression.
Age ≥ 21 years.
DSM-5 diagnosis of current Major Depressive Episode.
Montgomery-Asberg Depression Rating Scale score of 20 or more.
Inadequate response to an adequate trial (4 weeks) of at least one antidepressant medication.
DSM-5 psychotic disorder
Drug or alcohol abuse or dependence (preceding 3 months).
Rapid clinical response required, e.g., high suicide risk.
Significant neurological disorder, which may pose increased risks with TMS, e.g., epilepsy.
Institute of Mental Health, Singapore
Lead sponsor
National University of Singapore
Collaborator